Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Obama Signs 21st Century Cures Act Into Law

XTALKS VITALS NEWS

Obama

The legislation will allocate $1.8 billion for a cancer research “moonshot” project, which has gained tremendous support from Vice President Joe Biden.

Share this!

December 15, 2016 | by Sarah Hand, M.Sc.

This week, President Barack Obama signed the 21st Century Cures Act – a bill that promises additional funding for cancer research and opioid addiction prevention – into law. The legislation will allocate $1.8 billion for a cancer research “moonshot” project, which has gained tremendous support from Vice President Joe Biden.

In all, the 21st Century Cures Act will provide $6.3 billion in additional funding towards multiple large-scale projects. Under the bill, states will be provided with $1 billion in funding over a two year period to use towards the prevention and treatment of opioids and other drug addictions.



The bill will also change the way the US Food and Drug Administration (FDA) approves new drugs, potentially allowing them to accept alternative data sources to expedite the approvals process. Patient advocacy groups like Public Citizen have been strongly opposed to this part of the act, arguing that it will weaken the drug approvals process.

“This bill remains a bad deal for patient safety, offering a small, temporary and non-guaranteed increase in public research funding at the expense of permanently weakening oversight by the Food and Drug Administration,” said a spokesperson from Public Citizen. The group is a non-profit organization that aims to represent all US citizens, and their interests, in Washington, D.C.

The signing event represented a rare moment of bipartisanship, with both parties offering their support for the bill. “I hope this bodes well for what will come next year - that we're back working together,” said Biden.

The 21st Century Cures Act was passed in the US House of Representatives earlier this month in a landslide 392 to 26 vote. As predicted, the bill easily passed through the Senate to allow it to be signed into law before the close of 2016.


Keywords: Cancer, FDA, Opioids


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Study Finds Hospital-Acquired Anemia Linked with Poorer Patient Outcomes

May 19, 2017 - New research conducted at UT Southwestern Medical Center has found that one in three patients admitted to hospital develop anemia as a result.

Featured In: Life Science News


Scott Gottlieb Takes the Helm of the FDA

May 18, 2017 - One of the first things on his regulatory agenda is to address drug pricing – a hot topic in the US pharmaceutical industry today.

Featured In: Pharmaceutical News


Opioid Prescriptions for Minor Injuries Contribute to Growing Epidemic

May 18, 2017 - While many assume that patients prescribed large quantities of opioid drugs – such as oxycodone – for chronic pain are at the highest risk of abuse and dependence, new research suggests that small prescriptions for these narcotic painkillers could be just as dangerous.

Featured In: Drug Safety News


LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

Top 5 Most Impactful Tweets in Life Sciences During the Last Week

REGISTER FOR THESE WEBINARS

The ABCs of Assessing Cognition in Oncology Clinical Trials: Applications, Benefits, and Considerations


Respiratory Endpoints, Scientific Leadership and the Asia-Pacific Region


Imaging Diagnostics and Theranostics: Meeting Clinical Development Challenges


Enabling Patient-Centric Digital Transformation in Pharma and Biotech


Copyright © 2016-2017 Honeycomb Worldwide Inc.